1. Home
  2. RYTM vs LAD Comparison

RYTM vs LAD Comparison

Compare RYTM & LAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

SELL

Current Price

$88.80

Market Cap

6.3B

Sector

Health Care

ML Signal

SELL

Logo Lithia Motors Inc.

LAD

Lithia Motors Inc.

SELL

Current Price

$295.05

Market Cap

6.3B

ML Signal

SELL

Company Overview

Basic Information
Metric
RYTM
LAD
Founded
2008
1946
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail-Auto Dealers and Gas Stations
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.3B
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
RYTM
LAD
Price
$88.80
$295.05
Analyst Decision
Buy
Buy
Analyst Count
18
15
Target Price
$140.35
★ $421.40
AVG Volume (30 Days)
★ 714.2K
314.5K
Earning Date
11-03-2026
10-21-2026
Dividend Yield
N/A
★ 0.99%
EPS Growth
★ 28.34
9.01
EPS
N/A
★ 15.68
Revenue
N/A
★ $11,821,400,000.00
Revenue This Year
$66.00
$1.89
Revenue Next Year
$78.72
$3.18
P/E Ratio
★ N/A
$17.94
Revenue Growth
N/A
★ 17.20
52 Week Low
$74.50
$239.78
52 Week High
$122.20
$439.49

Technical Indicators

Market Signals
Indicator
RYTM
LAD
Relative Strength Index (RSI) 32.83 38.61
Support Level $82.43 $283.88
Resistance Level $92.51 $302.28
Average True Range (ATR) 3.39 12.13
MACD -0.22 0.85
Stochastic Oscillator 24.07 39.39

Price Performance

Historical Comparison
RYTM
LAD

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About LAD Lithia Motors Inc.

Lithia Motors is a retailer of new and used vehicles and related services. The company offers nearly 60 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US. We expect more deals over time in the US and, at times, abroad. Annual revenue in 2025 was $37.6 billion, and we see over $50 billion possible in a few years. The US was 78.5% of 2025 revenue and the UK second at 18.4%, due to the 2024 Pendragon acquisition. In 2025, new vehicle sales were about 50% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.

Share on Social Networks: